for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding AG

ROG.S

Latest Trade

292.50CHF

Change

-1.40(-0.48%)

Volume

484,477

Today's Range

290.55

 - 

294.60

52 Week Range

265.75

 - 

357.85

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
293.90
Open
291.15
Volume
484,477
3M AVG Volume
37.00
Today's High
294.60
Today's Low
290.55
52 Week High
357.85
52 Week Low
265.75
Shares Out (MIL)
854.64
Market Cap (MIL)
254,239.00
Forward P/E
--
Dividend (Yield %)
--

Next Event

Roche Holding AG at Credit Suisse Healthcare Conference (Virtual)

Latest Developments

More

SAP, Roche And Tenthpin To Create New Standard For Clinical Trial Supplies Operation

Roche Announces Chinese Approval For Tecentriq In Combination With Avastin

Ptc Therapeutics Inc Says Evrysdi Approved In Brazil By National Health Surveillance Agency For Treatment Of Spinal Muscular Atrophy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding AG

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry

Major Drugs

Contact Info

Grenzacherstr. 124

4058

Switzerland

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Fritz Gerber

Honorary Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Key Stats

2.00 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2017

53.3K

2018

56.8K

2019

61.5K

2020(E)

61.6K
EPS (CHF)

2017

15.340

2018

18.140

2019

20.160

2020(E)

19.666
Price To Earnings (TTM)
19.68
Price To Sales (TTM)
4.22
Price To Book (MRQ)
7.99
Price To Cash Flow (TTM)
14.06
Total Debt To Equity (MRQ)
47.74
LT Debt To Equity (MRQ)
39.64
Return on Investment (TTM)
25.22
Return on Equity (TTM)
17.03

Latest News

Latest News

Roche, Atea team up on potential COVID-19 pill

Roche Holding and Atea Pharmaceuticals have joined forces to develop an antiviral oral treatment called AT-527, now in phase 2 clinical trials, as a potential treatment for COVID-19 patients, the companies said on Thursday.

Roche, Blueprint lung cancer drug wins FDA approval

Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).

Roche-PTC Therapeutics' oral spinal muscular atrophy drug wins FDA approval

The U.S. Food and Drug Administration on Friday approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc for spinal muscular atrophy in adults and children two months and above.

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

BRIEF-Roche Announces Data For Treatment Of Haemophilia A

* ROCHE ANNOUNCES NEW DATA AT ISTH 2020 CONGRESS, DEMONSTRATING ONGOING COMMITMENT TO ADVANCING CARE FOR PEOPLE WITH HAEMOPHILIA A

BRIEF-Roche’s Enspryng Approved In Japan For Patients With Neuromyelitis Optica Spectrum Disorder

* ROCHE’S ENSPRYNG®️ (SATRALIZUMAB) APPROVED IN JAPAN FOR ADULTS AND CHILDREN WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

BRIEF-Roche Launches Algorithm For Diagnosing Lung Cancer

* ROCHE IMPROVES SPEED AND ACCURACY OF NON-SMALL CELL LUNG CANCER DIAGNOSIS WITH LAUNCH OF AUTOMATED DIGITAL PATHOLOGY ALGORITHM

BRIEF-Roche Gets FDA Approval For Cobas EZH2 Mutation Test As Companion Diagnostic For Tazverik Developed By Epizyme

* ROCHE RECEIVES FDA APPROVAL FOR COBAS EZH2 MUTATION TEST AS A COMPANION DIAGNOSTIC FOR PATIENTS WITH FOLLICULAR LYMPHOMA

BRIEF-Roche Holding AG - Impassion031 Study Is The Second Positive Phase Iii Study From Roche Demonstrating The Benefit Of Tecentriq In Tnbc

* ROCHE HOLDING AG - TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY MEETS PRIMARY ENDPOINT OF IMPROVED PATHOLOGICAL COMPLETE RESPONSE AS INITIAL TREATMENT FOR PEOPLE WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

BRIEF-Roche Holding Says Tecentriq With Chemotherapy Meets Primary Endpoint

* ROCHE’S TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY (INCLUDING ABRAXANE) MEETS PRIMARY ENDPOINT OF IMPROVED PATHOLOGICAL COMPLETE RESPONSE, REGARDLESS OF PD-L1 STATUS, AS INITIAL TREATMENT FOR PEOPLE WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

BRIEF-SpeedDx And Roche Partner To Expand Access To Antibiotic Resistance Tests

* SPEEDX AND ROCHE PARTNER TO EXPAND ACCESS TO ANTIBIOTIC RESISTANCE TESTS

BRIEF-Roche Reports Positive Phase 3 Results For Venclexta/Venclyxto Combination In Acute Myeloid Leukaemia

* POSITIVE PHASE III RESULTS FOR VENCLEXTA/VENCLYXTO COMBINATION IN ACUTE MYELOID LEUKAEMIA PRESENTED AT EHA 2020

BRIEF-Roche Announces 2-Year Risdiplam Data From Sunfish

* ROCHE ANNOUNCES 2-YEAR RISDIPLAM DATA FROM SUNFISH AND NEW DATA FROM JEWELFISH IN INFANTS, CHILDREN AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA)

BRIEF-Innovent Biologics Says Unit Entered Strategic Collaboration Agreement With Roche Group

* UNIT ENTERED STRATEGIC COLLABORATION AGREEMENT WITH ROCHE GROUP

Roche's Genentech unit to face renewed Herceptin breast cancer drug litigation

A federal appeals court revived nationwide litigation accusing Roche Holding AG's Genentech unit of failing to ensure that vials of its Herceptin breast cancer drug contained the labeled amount of the active ingredient, and that the labels misstated the drug's concentration...

BRIEF-Roche: Updated Data On Roche's Alecensa

* UPDATED DATA DEMONSTRATE ROCHE’S ALECENSA INCREASES OVERALL SURVIVAL RATE FOR PEOPLE WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER

BRIEF-Roche Says Ocrevus Shorter 2-Hour Infusion Time Approved In Europe

* ROCHE'S OCREVUS (OCRELIZUMAB) SHORTER 2-HOUR INFUSION TIME APPROVED IN EUROPE

BRIEF-Roche Says Data Reinforce Safety Of Satralizumab In Neuromyelitis Patients

* NEW LONGER-TERM DATA REINFORCE SAFETY OF ROCHE’S SATRALIZUMAB IN ADULTS AND ADOLESCENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

Roche's Tecentriq wins FDA approval as first-line therapy for some lung cancer forms

(This May 18 story corrects paragraph 4 to say Tecentriq won "three" other NSCLC approvals and not "four")

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up